Monthly use of erenumab injections (140 mg) is safe and effective in achieving medication overuse headache (MOH) remission in patients with nonopioid chronic migraine (CM) and MOH, according to a study published online Sept. 16 in JAMA Neurology . Stewart J.
Tepper, M.D., from the New England Institute for Neurology and Headache in Stamford, Connecticut, and colleagues assessed the safety and efficacy of erenumab in patients with nonopioid CM-MOH.
The analysis included 584 participants randomly assigned to erenumab (70 mg or 140 mg) or placebo, once monthly for 24 weeks. The researchers found that at month 6, 69.1% of participants in the erenumab 140-mg group (odds ratio, 2.
01; 95% confidence interval, 1.33 to 3.05; P < 0.
001 versus placebo) and 60.3% in the erenumab 70-mg group (odds ratio, 1.37; 95% confidence interval, 0.
92 to 2.05; P = 0.13 versus placebo) achieved MOH remission versus 52.
6% of participants in the placebo group . From baseline, least squares mean change in average monthly acute headache medication days was –9.4 days in the erenumab 140-mg group (difference from placebo, –2.
7) and –7.8 days in the erenumab 70-mg group (difference from placebo, –1.2).
Throughout the treatment period, MOH remission was sustained in 61.3% of participants in the erenumab 140-mg group, 49.5% of participants in the 70-mg group, and 37.
6% in the placebo group. The safety profile was similar to that seen in previous trials, with treatment-emergent adverse event incidence i.